Ocugen

Ocugen is a clinical-stage biotechnology company focused on gene and cell therapies for blindness diseases, plus a biologics and vaccine pipeline. Founded in 2013 and headquartered in Malvern, it is best known for its modifier gene-therapy platform, led by a Phase 3 candidate for retinitis pigmentosa. The company drew wide public attention during the pandemic as the U.S. and Canada co-development partner for Bharat Biotech's Covaxin COVID-19 vaccine. It remains one of Malvern's most actively traded small-cap biotechs.